Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doxorubicin liposomal - CSPC Ouyi Pharmaceutical

Next Previous
X
Search
Drug Profile

Doxorubicin liposomal - CSPC Ouyi Pharmaceutical

Alternative Names: Duomeisu; Pegylated liposomal doxorubicin - CSPC Ouyi Pharmaceutical; PLD

Latest Information Update: 28 Dec 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSPC Ouyi Pharmaceutical
  • Developer CSPC Ouyi Pharmaceutical; CSPC ZhongQi Pharmaceutical Technology
  • Class Anthracyclines; Antineoplastics; Antivirals; Cytostatic antibiotics; Doxorubicins; Hepatoprotectants; Small molecules
  • Mechanism of Action DNA intercalators; Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Diffuse large B cell lymphoma; Lymphoma; Multiple myeloma; Ovarian cancer
  • No development reported Soft tissue sarcoma; Thyroid cancer

Most Recent Events

  • 28 Dec 2022 No recent reports of development identified for phase-I development in Soft tissue sarcoma(Combination therapy, Inoperable/Unresectable, Late-stage disease) in China (IV)
  • 09 Sep 2022 Efficacy and safety data from a phase II trial in Breast cancer presented at 47th European Society for Medical Oncology Congress (ESMO 2022)
  • 26 Jul 2022 No development reported - Phase-II for Thyroid cancer (Late-stage disease) in China (IV) (NCT03387943)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top